Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $11.45

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given an average rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $11.27.

Several brokerages recently weighed in on HCAT. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a research note on Wednesday, January 8th. Royal Bank of Canada dropped their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Evercore ISI upped their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Stephens increased their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th.

Health Catalyst Stock Down 4.5 %

NASDAQ:HCAT opened at $5.50 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company’s fifty day moving average price is $7.68 and its 200-day moving average price is $7.53. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $10.99. The firm has a market capitalization of $334.68 million, a P/E ratio of -4.07 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) earnings per share. As a group, equities research analysts anticipate that Health Catalyst will post -0.33 EPS for the current year.

Insider Buying and Selling

In other news, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at $721,443.84. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the sale, the chief operating officer now owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,727 shares of company stock worth $601,810. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds have recently modified their holdings of the business. Quest Partners LLC purchased a new stake in Health Catalyst during the 3rd quarter valued at about $34,000. Quarry LP grew its position in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $59,000. Quadrature Capital Ltd purchased a new position in Health Catalyst during the third quarter worth approximately $84,000. Finally, Mackenzie Financial Corp purchased a new position in Health Catalyst during the second quarter worth approximately $70,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.